Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2019’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)

- The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects

- The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Centauri Therapeutics Ltd

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Evaxion Biotech ApS

MedImmune ...

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Centauri Therapeutics Ltd

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Evaxion Biotech ApS

MedImmune LLC

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics Plc

Polyphor AG

Sealife PHARMA GMBH

Shionogi & Co Ltd

Spero Therapeutics Inc

Tetraphase Pharmaceuticals Inc

Wockhardt Ltd

Table of Contents

Table of Contents

Table of Contents

Introduction

Hospital Acquired Pneumonia (HAP) - Overview

Hospital Acquired Pneumonia (HAP) - Therapeutics Development

Hospital Acquired Pneumonia (HAP) - ...

Table of Contents

Table of Contents

Introduction

Hospital Acquired Pneumonia (HAP) - Overview

Hospital Acquired Pneumonia (HAP) - Therapeutics Development

Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment

Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development

Hospital Acquired Pneumonia (HAP) - Drug Profiles

Hospital Acquired Pneumonia (HAP) - Dormant Projects

Hospital Acquired Pneumonia (HAP) - Discontinued Products

Hospital Acquired Pneumonia (HAP) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Companies, H1 2019 (Contd..3), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019

Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2019

Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2019

Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2019 (Contd..1), H1 2019

Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports